Cobimetinib/Vemurafenib OS Benefit Sustained at 5 Years in BRAF+ Melanoma

Source: OncLive, December 2019

Combining the MEK inhibitor cobimetinib (Cotellic) with the BRAF inhibitor vemurafenib (Zelboraf) provides long-term clinical benefits for patients with BRAF V600–mutated metastatic melanoma. Data from a final analysis of the phase III coBRIM trial presented at the 16th International Congress of the Society for Melanoma Research showed that the combination maintained an advantage for overall survival (OS) and objective response rate (ORR) compared with vemurafenib alone at 5 years.1

Cobimetinib/vemurafenib improved OS and progression-free survival (PFS) by roughly 5 months compared with vemurafenib alone. The median OS was 22.5 months (95% CI, 20.3-28.8) with the combination compared with 17.4 months (95% CI, 14.5-19.8) for the monotherapy. The 5-years OS rates were 30.8% vs 26.3%, respectively.

“In all subgroup analyses, the OS favored the cobimetinib/vemurafenib arm,” said lead author Grant A. McArthur, PhD, head of the Molecular Oncology Laboratory and of the Cancer Therapeutics Program at the Peter MacCallum Cancer Centre in Melbourne, Australia. “This included the poor prognosis M1c patients, the ECOG performance status 1 patients, patients who had the V600K mutation, and, of course, the LDH patient populations.”

Menu